Monoclonal Antibody Based Products : Market Research Report

Monoclonal Antibody Based Products

Published by: Global Industry Analysts

Published: Oct. 1, 2008 - 527 Pages

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Quantitative Techniques & Analytics; Cancer
II. EXECUTIVE SUMMERY: 1. Industry Overview; World MAb-Based Products Market: A Profile; Therapeutic mAb Market - Principal Driving Force; Genomics Research Leads Way to New Monoclonal Antibodies; Product Segment Perspective; Table 1: Major Acquisitions of Antibody-Focused Companies (2005-2007); Table 3: Leading Drugs in the Global Therapeutic Monoclonal Antibodies Market (2006): Percentage Breakdown of Dollar Sales for Remicade, Rituxan, Herceptin, Avastin, Humira, Erbitux, Synagis, Xolair and Others (includes corresponding Graph/Chart); Table 6: Leading Products in the Global Oncology Monoclonal Antibodies Market (2008E): Percentage Share Breakdown of Sales for Avastin, Herceptin, Rituxan, Erbitux, and Others (includes corresponding Graph/Chart); Drug Developers Trying to Break the Shackles; A Revolution Not too Far; Evolution of Monoclonal Antibodies - A Historical Journey; Trends and Issues; Partnerships and Collaborations Spark Increase in Profit Margins; Select Clinical Trials for Monoclonal Antibodies; Major Monoclonal Antibodies in Phase III Trials Across the World; Opportunities in Technology Development; FCA- A Major Cause for Discomfort in Mice; Immune System: Natural Defenders; Polyclonal and Monoclonal Antibodies; Factors Impacting Production of MAbs; Humanized Antibodies/ CDR Grafted Antibodies; Chimeric Antibodies: Show Lesser Antigenicity; Advantages of MAbs; 4. Diagnostic Applications of Monoclonal Antibodies; Monoclonal Antibody Based Diagnostics; The Pros and Cons of MAb-Based Immunoconjugates; Cancer; 5. Monoclonal Antibody-Based Therapeutics; Evolution of Therapeutic Antibody Products; Current Scenario in Monoclonal Antibody Therapeutics Market; Cancer Therapeutics; Monoclonal Antibody Cancer Therapies Under Development; Cancer: A Serious Issue and Plaguing Illness Worldwide; Monoclonal Antibodies Against NHL; Immunologic Effector Functions; 6. Other Therapeutic Monoclonal Antibodies; Therapeutic Monoclonal Antibody Drugs and Applications; Asthma: A Chronic Affliction; Intervention Better Than Prevention; Crohn’s Disease; Syngeneic Transplants; Infectious Diseases; A Retrospect; Global Statistics; Treatment Options; 7. Regulation Impacting The Industry; Regulations in the U.S; Orphan Drug Status; 8. Research and Development Activities; Rituxan and Herceptin from Genentech; GenMAb Develops Fully Human Antibodies; 9. Product Launches and Developments; Amgen Introduces Vectibix; Dr. Reddy’s Introduces Reditux™; Genentech Introduces Xolair; 10. Recent Industry Activity; EUSA Pharma to Take Over Cytogen; Access Pharmaceuticals Acquires Somanta Pharmaceuticals; Genmab Enters into Antibody Research Collaboration with Pepscan; Eusa Sells Antibody Research Business; HGS Reacquires Rights for TRAIL Receptor Antibodies; Dyax and Sanofi-Aventis Sign Agreements; CSL Limited Inks a Collaboration Agreement with Celltrion; Astellas US Holding Takes Over Agensys; Genentech Acquires Tanox; GTC and LFB Commence CD20 Monoclonal Antibody Development; BioArctic and Eisai Announce Licensing Agreement; CMC Biopharmaceuticals Inks Agreement with Biotest; Abeome Enters into Distribution Agreement with Millipore; Favrille Acquires Diversa’s Anti-CD20 Monoclonal Antibodies; Merck Acquires Abmaxis; Xencor Extends R&D Collaboration with Roche; Akorn and Serum Institute Enter into Development and Distribution Agreement; Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal Antibody Drug; Candidates; Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for Cancer; Treatment; Therapeutics; Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business; XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal; Antibodies; UCB Collaborates with Millenium; H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics; Research; ImmunoGen Signs Licensing Agreement with Biogen; MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials; CAT Signs Licensing Agreement with Micromet; InNexus and Corixa Enter into Agreement; Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody; Research; Epicyte and Dow Chemical Enter into Agreement; PDL Signs Agreement with InterMune; MedImmune and Alkermes Enter into Agreement; Amgen, Inc. (US); Biogen Idec Inc (US); CMC ICOS Biologics, Inc; Eli Lilly and Company (US); Human Genome Sciences, Inc. (US); Johnson & Johnson (US); Ortho Biotech Products, L.P. (US); PDL BioPharma (US); Strategic Diagnostics Inc (US); 13. Global Market Perspective; Table 10: World Recent Past, Current & Future Market Analysis for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 11: World Long-term Projections for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 12: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 13: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 14: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 15: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 16: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment - Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 18: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Segments - Percentage Breakdown of Dollar Sales for Cancer and Other Therapeutics Markets for Years 2003, 2008 & 2012; Table 19: World Recent Past, Current & Future Market Analysis for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 20: World Long-term Projections for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 21: World 10-Year Perspective for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 22: World Recent Past, Current & Future Market Analysis for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 23: World Long-term Projections for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 24: World 10-Year Perspective for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 25: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 26: World Long-term Projections for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 27: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
III. MARKET: 1. The Untied States; A. Market Analysis; Therapeutic Monoclonal Antibodies Market - An Overview; Leading Products; Table 29: Leading Players in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Share Breakdown of Revenues for Genentech Inc, Centocor, MedImmune, Bristol Meyer's Squibb, Amgen, Hoffman-La Roche, and Others (includes corresponding Graph/Chart); BD Biosciences; CMC ICOS Biologics, Inc; Eli Lilly and Company; Immunomedics; Johnson & Johnson; MedImmune, Inc; PDL BioPharma; Wyeth Pharmaceuticals; Strategic Developments; B. Market Analytics; Table 32: US 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 2. Canada; A. Market Analysis; Strategic Developments; B. Market Analytics; Table 35: Canadian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 3. Japan; A. Market Analysis; B. Market Analytics; Table 38: Japanese 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4. Europe; A. Market Analysis; Need to Reduce Complexities, Time & Cost of mAb Development; Emerging Radioimmunotherapy Products; B. Market Analytics; Table 41: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 43: European 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region -Percentage Breakdown of Dollar Sales for France, Germany, Italy, The UK, and Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 44: European 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4a. France; A. Market Analysis; B. Market Analytics; Table 47: French 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4b. Germany; A. Market Analysis; Strategic Developments; B. Market Analytics; Table 50: German 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4c. Italy; Market Analysis; Table 52: Italian Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 53: Italian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4d. The United Kingdom; A. Market Analysis; Product Launches; B. Market Analytics; Table 56: UK 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4e. Rest of Europe; A. Market Analysis; Strategic Developments; B. Market Analytics; Table 58: Rest of Europe Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 59: Rest of Europe 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 5. Rest of World; A. Market Analysis; B. Market Analytics; Table 62: Rest of World 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE: Total Companies Profiled: 123 (including Divisions/Subsidiaries - 144); Region/Country Players; The United States 89; Canada 6; Japan 6; Europe33; France5; Germany 7; The United Kingdom6; Italy 1; Spain 1; Rest of Europe 13; Asia-Pacific (Excluding Japan) 9; Middle-East1

Abstract

This report analyzes the worldwide markets for Monoclonal Antibody Based Products in Millions of US$. The major product segments and application areas analyzed are Therapeutics, and Diagnostics, especially for cancer. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of world. Annual forecasts are provided for each region for the period of 2003 through 2015. The report profiles 123 companies including many key and niche players worldwide such as Amgen, Inc., BD Biosciences, Biogen Idec, CMC ICOS Biologics, Inc., Dendreon Corporation, Eli Lilly and Company, Genentech, Inc., Human Genome Sciences, Inc., Immunomedics, Johnson & Johnson, Centocor, Ortho Biotech Products, L.P., Medarex Inc, Medlmmune Inc, PDL BioPharma, Schering-Plough Corporation, Strategic Diagnostics Inc., and Wyeth Pharmaceuticals. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 30

Monoclonal Antibody Based Products

Table of Contents

Abstract